Sequential analysis of viral load in lymph nodes of SIV infected rhesus macaques: correlates with disease evolution. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Sequential analysis of viral load in lymph nodes of SIV infected rhesus macaques: correlates with disease evolution.

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 23. Unique Identifier : AIDSLINE PRIM11/94191616
Chakrabarti L; Cumont MC; Montagnier L; Hurtrel B; Unite d'Oncologie Virale, Institut Pasteur, Paris, France.


Abstract: Lymphoid organs are now recognized as the major reservoir of HIV and SIV viruses in the organism. To elucidate the initial pathogenic events in these organs, we performed a quantitative follow up of viral load and pathologic changes in lymph nodes (LN) early in the course of SIV infection. 8 Rhesus macaques were inoculated intravenously with 3.10(3) TCID50 (4 animals) or 10 TCID50 (4 animals) of the SIVmac251 isolate. LN and PBMC were collected at days 7, 14, 35, and 68 p.i. and analyzed by in situ hybridization and immunohistochemistry. The initial viral load in LN was comparable for the 4 high-dose animals, with a mean number of 50 infected cells per mm2 of tissue section at 7 days p.i. However, infection in these 4 animals evolved differently. In 3 cases, high levels of viral RNA persisted in the germinal centers (GC) of the follicles at 14, 35 and 68 days p.i. The animal with the highest viral load in GC and persistence of productively infected cells in the LN parenchyma showed a rapid course of disease and had to be sacrificed at 255 days p.i. Among the other 2 animals, one showed signs of disease progression such as marked CD4 loss while the other had episodes of thrombocytopenia. For the 4th animal, which has remained healthy, viral RNA persisted in low amounts in the GC at 35 days p.i., and was no longer detectable from 68 days p.i. onwards. Immunolabelling of LN sections showed that rapid disease evolution was associated with a marked increase in the number of activated macrophages in the sinuses, detectable as early as 7 days p.i., and with the presence of CD8+ cell foci in the germinal centers. A similar study is in progress for the 4 low dose animals. Initial results show that the viral load reached in LN is as high as with a larger inoculum, though the peak of infected cells appears one week later. In conclusion, this study suggests that the determination of viral load in LN early in infection could represent a valuable indicator of the risk of progression towards the clinical stage of the infection.
Keywords: Animal Antigens, CD4/ANALYSIS Antigens, CD8/ANALYSIS Immunohistochemistry In Situ Hybridization Lymph Nodes/*MICROBIOLOGY/PATHOLOGY Macaca mulatta RNA, Viral/ANALYSIS Simian Acquired Immunodeficiency Syndrome/IMMUNOLOGY/PATHOLOGY/ *PHYSIOPATHOLOGY SIV/GENETICS/*ISOLATION & PURIF/PHYSIOLOGY T-Lymphocyte Subsets/IMMUNOLOGY Time Factors ABSTRACTKWDanimalantigens,cd4/analysisantigens,cd8/analysisimmunohistochemistryinsituhybridizationlymphnodes/KWDmicrobiology/pathologymacacamulattarna,viral/analysissimianacquiredimmunodeficiencysyndrome/immunology/pathology/KWDphysiopathologysiv/genetics/KWDisolation&purif/physiologyt-lymphocytesubsets/immunologytimefactorsabstract
940730
M9470902

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .